Evidence map›Paper›PMID 27027803›Full record

ArticleCancer science2016

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.

Keisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, Naoya Nakamura, Koichi Ohshima, Hirohito Sone, Jun Takizawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Deep learning shows the capability of high-level computer-aided diagnosis in malignant lymphoma.Laboratory investigation; a journal of technical methods and pathology · 2020
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. The impact ofInternational journal of clinical and experimental pathology · 2019
    Article
  16. Article
  17. Article
  18. Review
  19. Clinicopathological features of cryptococcal lymphadenitis and a review of literature.Journal of clinical and experimental hematopathology : JCEH · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Keisuke KawamotoDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Hiroaki MiyoshiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Noriaki YoshidaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Naoya NakamuraDepartment of Pathology, Faculty of Medicine, Tokai University, Isehara, Japan.
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Hirohito SoneDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Kurume University · JPNiigata University · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genomic alterations and protein expression levels have been established as prognostic factors for survival in patients with diffuse large B-cell lymphoma (DLBCL). In particular, double-hit DLBCL (DHL), which exhibits translocations in MYC and BCL2 and/or BCL6, is known to be associated with a poor prognosis. However, the clinical significance of gene alterations and protein expression levels for MYC, B-cell lymphoma (BCL)2, and BCL6 are unclear. In this study, we analyzed 61 adult patients diagnosed with DLBCL without DHL, who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, or similar regimens. There were no differences in the distribution of MYC expression rates among the different MYC gene statuses. In log-rank tests, MYC translocation was a prognostic factor for overall survival (OS; P = 0.011), whereas BCL2 and BCL6 translocation were not prognostic indicators (P = 0.999 and P = 0.925, respectively). Although the expression levels of MYC and BCL6 were not significantly associated with OS, the expression of BCL2 was a prognostic factor for OS (P = 0.027). Furthermore, copy number gains in the MYC, BCL2, and BCL6 genes did not affect OS. MYC translocation (hazard ratio, 4.769; range, 1.518-14.98; P = 0.007) and BCL2 protein expression (hazard ratio, 3.072; range, 1.002-9.413; P = 0.049) were independent prognostic factors for survival in multivariate analyses. In conclusion, MYC translocation and BCL2 expression may need to be investigated at the initial diagnosis to predict prognosis in patients with DLBCL.

Indexed as

Genes, mycAdolescentAdultAgedAged, 80 and overCyclophosphamideDoxorubicinFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisolonePrognosisProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6BCL2 protein, humanBCL6 protein, humanCyclophosphamideDoxorubicinPrednisoloneProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6RituximabVincristineBCL2BCL6diffuse large B-cell lymphomaMYCprognostic factor

Identifiers

PMID27027803
PMCPMC4968597
OpenAlexW2315415505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.